Nuvectis Historical Balance Sheet
| NVCT Stock | USD 9.32 0.49 4.99% |
Trend analysis of Nuvectis Pharma balance sheet accounts such as Total Stockholder Equity of 5.5 M provides information on Nuvectis Pharma's total assets, liabilities, and equity, which is the actual value of Nuvectis Pharma to its prevalent stockholders. By breaking down trends over time using Nuvectis Pharma balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.
Nuvectis |
About Nuvectis Balance Sheet Analysis
Balance Sheet is a snapshot of the financial position of Nuvectis Pharma at a specified time, usually calculated after every quarter, six months, or one year. Nuvectis Pharma Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Nuvectis Pharma and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Nuvectis currently owns. An asset can also be divided into two categories, current and non-current.
Nuvectis Pharma Balance Sheet Chart
Add Fundamental
Total Current Liabilities
Total Current Liabilities is an item on Nuvectis Pharma balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Nuvectis Pharma are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Accounts Payable
An accounting item on the balance sheet that represents Nuvectis Pharma obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Nuvectis Pharma are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.Cash And Short Term Investments
Short Term Investments is an account in the current assets section of Nuvectis Pharma balance sheet. This account contains Nuvectis Pharma investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Nuvectis Pharma fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.Non Currrent Assets Other
Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.Most accounts from Nuvectis Pharma's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Nuvectis Pharma current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nuvectis Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Nuvectis Stock please use our How to Invest in Nuvectis Pharma guide.At this time, Nuvectis Pharma's Net Tangible Assets are comparatively stable compared to the past year. Other Current Assets is likely to gain to about 116.3 K in 2025, whereas Total Assets are likely to drop slightly above 15.7 M in 2025.
| 2022 | 2023 | 2024 | 2025 (projected) | Cash | 20.0M | 19.1M | 18.5M | 15.2M | Accounts Payable | 2.9M | 2.8M | 2.5M | 2.0M |
Nuvectis Pharma balance sheet Correlations
Click cells to compare fundamentals
Nuvectis Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Nuvectis Stock Analysis
When running Nuvectis Pharma's price analysis, check to measure Nuvectis Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nuvectis Pharma is operating at the current time. Most of Nuvectis Pharma's value examination focuses on studying past and present price action to predict the probability of Nuvectis Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nuvectis Pharma's price. Additionally, you may evaluate how the addition of Nuvectis Pharma to your portfolios can decrease your overall portfolio volatility.